Pain Management
Alpharma receives U.S. FDA approval for Kadian 80 mg capsules
Published in Biotech Business Week, November 27th, 2006
The company expects to launch this new dosage strength in the fourth quarter of 2006. Kadian is Alpharma's branded sustained release morphine sulfate product and is currently marketed in 20 mg, 30 mg, 50 mg, 60 mg and 100 mg dosages. The added dosage strength is intended to assist in physicians efforts to individualize their patient's treatments by offering more choices in managing their pain.
The company has conducted in vivo studies to evaluate the interaction of alcohol consumption...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
More Articles from Biotech Business Week
- Healthcare Costs
Principal Financial Group survey shows rising healthcare costs hurting household savings - Market Analysis
More consumer-direct fall enrollment options seen for employees but employers cool to plans - Market Analysis
Worldwide catheter market is poised for growth - Mergers & Acquisitions
Ciphergen stockholders approve sale of proteomics instrument business to Bio-Rad Laboratories - Mergers & Acquisitions
Merck & Co. to acquire RNA developer Sirna Therapeutics in deal worth $1.1 billion - Pharmacology
Studies from Cornell University, Institute for Computational Biomedicine in the area of pharmacology published - More from this issue of Biotech Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
